With plans for a major expansion of its North Carolina site, Fresenius Kabi’s investments aimed primarily at the U.S. generics market now top $5 billion as the German drugmaker bets on growth in sterile injectables.
Fresenius Kabi says it will spend more than $100 million and add 445 jobs at the syringe and drug-making site in Wilson, North Carolina, that it acquired in 2016 from Becton Dickinson. Fresenius has agreed to add the jobs over five years in exchange for about $7.2 million in state aid over 12 years. The company will build a second manufacturing facility there as well as add to the current facility.
That project comes on top of the $250 million the drugmaker is investing in a sterile injectables manufacturing site in Melrose, Illinois, near its U.S. headquarters in Lake Zurich, Illinois. It recently broke ground on that project.
Its biggest bet, however, was the $4.75 billion it agreed in April to pay for U.S.-based generics maker Akorn, which specializes in sterile injectables but also has a portfolio of products spanning new dosage forms for Fresenius, including sterile ophthalmics, topical creams, ointments and gels.
“Our strategy is to produce in the U.S. and to invest in products and operations that meet important customer needs while helping make healthcare more accessible for patients,” Steven R. Nowicki, senior VP of global operations for Fresenius Kabi North America, said in a statement. “We’re pleased to continue this approach at our site in North Carolina.”
The Akorn deal is slated to close early next year. It will add three U.S. manufacturing sites and one in India to Fresenius’ network, as well as about 2,000 employees.
On the same day that Fresenius announced plans to buy Akorn, it said it would also pay €170 million up front and up to €500 million in milestone payments, or about $729.2 million total, to buy the biosimilars portfolio of Germany-based Merck KGaA. With its expanded sterile injectables portfolio and move into biosimilars, Fresenius appears to be mimicking the approach taken by sterile injectables leader Hospira, which Pfizer bought in 2015 for $15 billion.
By Eric Palmer
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
